BeyondSpring Inc. (BYSI)

$1.56

+0.12 (+8.33%)
Rating:
Recommendation:
Strong Buy
Symbol BYSI
Price $1.56
Beta 1.198
Volume Avg. 0.37M
Market Cap 60.729M
Shares () -
52 Week Range 1.13-33.0
1y Target Est -
DCF Unlevered BYSI DCF ->
DCF Levered BYSI LDCF ->
ROE -133.13% Strong Sell
ROA -78.60% Strong Sell
Operating Margin -
Debt / Equity 227.57% Strong Buy
P/E -
P/B 2.28 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BYSI news


Dr. Lan Huang
Healthcare
Biotechnology
NASDAQ Capital Market

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.